Notable Mover: What’s Propelling The Medicines Company to Increase So Much?

Notable Mover: What's Propelling The Medicines Company to Increase So Much?

The stock of The Medicines Company (NASDAQ:MDCO) is a huge mover today! About 1.47M shares traded hands. The Medicines Company (NASDAQ:MDCO) has risen 8.75% since April 14, 2016 and is uptrending. It has outperformed by 4.06% the S&P500.
The move comes after 6 months positive chart setup for the $2.75 billion company. It was reported on Nov, 16 by Barchart.com. We have $64.60 PT which if reached, will make NASDAQ:MDCO worth $1.87B more.

The Medicines Company (NASDAQ:MDCO) Ratings Coverage

Out of 4 analysts covering The Medicines Co (NASDAQ:MDCO), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. The Medicines Co has been the topic of 12 analyst reports since August 28, 2015 according to StockzIntelligence Inc. The firm earned “Market Perform” rating on Monday, August 31 by Oppenheimer. The rating was maintained by Leerink Swann on Monday, August 31 with “Buy”. Chardan Capital Markets initiated it with “Buy” rating and $50 target price in Wednesday, November 4 report. On Friday, August 28 the stock rating was upgraded by Jefferies to “Hold”. The stock of The Medicines Company (NASDAQ:MDCO) earned “Buy” rating by JP Morgan on Saturday, August 29. RBC Capital Markets maintained The Medicines Company (NASDAQ:MDCO) rating on Tuesday, November 8. RBC Capital Markets has “Outperform” rating and $45 price target. RBC Capital Markets maintained it with “Outperform” rating and $48 target price in Monday, November 16 report. The firm has “Buy” rating by Chardan Capital Markets given on Monday, March 21. RBC Capital Markets maintained the stock with “Outperform” rating in Monday, August 31 report.

According to Zacks Investment Research, “Medicines Company acquires, develops and commercializes biopharmaceutical products in late stages of development. U.S. Food and Drug Administration intends to approve its first product, Angiomax, for use in the treatment of patients with unstable angina undergoing coronary balloon angioplasty. The company is also developing Angiomax for additional potential applications for use in the treatment of ischemic heart disease, a condition which occurs when organs receive an inadequate supply of oxygen as a result of decreased blood flow.”

Insitutional Activity: The institutional sentiment increased to 1.27 in Q2 2016. Its up 0.14, from 1.13 in 2016Q1. The ratio improved, as 20 funds sold all The Medicines Company shares owned while 54 reduced positions. 25 funds bought stakes while 69 increased positions. They now own 81.19 million shares or 0.45% less from 81.56 million shares in 2016Q1.
Group Incorporated One Trading Lp owns 26,075 shares or 0.01% of their US portfolio. First Mercantile Com has 3,400 shares for 0.01% of their US portfolio. Franklin Res Inc accumulated 1.45M shares or 0.03% of the stock. Royal London Asset Mngmt Limited has invested 0.03% of its portfolio in The Medicines Company (NASDAQ:MDCO). Ladenburg Thalmann Financial Service last reported 0% of its portfolio in the stock. Envestnet Asset Mngmt owns 4,218 shares or 0% of their US portfolio. Moreover, Arizona State Retirement System has 0.02% invested in The Medicines Company (NASDAQ:MDCO) for 36,096 shares. Essex Limited Liability has invested 0.07% of its portfolio in The Medicines Company (NASDAQ:MDCO). Opus Point Ptnrs Mngmt Limited Liability Com holds 13,885 shares or 0.45% of its portfolio. Sei Invests Company last reported 1,151 shares in the company. Walleye Trading Limited Com holds 0% of its portfolio in The Medicines Company (NASDAQ:MDCO) for 9,231 shares. Blackrock Institutional Trust Com Na last reported 1.68M shares in the company. Amer Century Companies Inc has 57,652 shares for 0% of their US portfolio. Aperio Llc last reported 0.01% of its portfolio in the stock. Royal Bank Of Canada last reported 0% of its portfolio in the stock.

Insider Transactions: Since May 24, 2016, the stock had 2 insider buys, and 5 selling transactions for $1.62 million net activity. 15,000 shares were sold by Spigelman Melvin K, worth $555,000. $369,500 worth of shares were sold by Savage Robert G. on Tuesday, May 24. MEANWELL CLIVE sold $800,000 worth of The Medicines Company (NASDAQ:MDCO) on Wednesday, August 24. Cox Christopher T bought 45,985 shares worth $1.74 million.

More notable recent The Medicines Company (NASDAQ:MDCO) news were published by: Businesswire.com which released: “The Medicines Company and Alnylam Pharmaceuticals Present Positive Results …” on November 15, 2016, also Fiercebiotech.com with their article: “The Medicines Company drops MDCO-216 as med comes up short” published on November 08, 2016, Businesswire.com published: “Alnylam Pharmaceuticals and The Medicines Company Announce Publication of …” on November 13, 2016. More interesting news about The Medicines Company (NASDAQ:MDCO) were released by: Businesswire.com and their article: “The Medicines Company to Host Conference Call and Webcast to Review Data from …” published on November 10, 2016 as well as Businesswire.com‘s news article titled: “The Medicines Company Announces Positive Top-Line Results from Day 90 Interim …” with publication date: October 18, 2016.

MDCO Company Profile

The Medicines Company, incorporated on July 31, 1996, is a global biopharmaceutical company. The Company’s marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). The Company’s pipeline of acute and intensive care hospital products in development include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. The Firm sells a ready to use formulation of Argatroban and has a portfolio of over 10 generic drugs, which is referred as acute care generic products. The Firm sells over three of its acute care generic products, including midazolam, ondansetron and rocuronium.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment